Back to results
US 2017/0247363 A1Published application
Cytochrome p450 inhibitors and uses thereof
AssigneeAngion Biomedica Corp.
InventorBijoy PANICKER
Life of this patent
Estimating the term…
Abstract
The present invention provides compounds having the general structural formula (I) (I) and pharmaceutically acceptable derivatives thereof, as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof for the treatment of any of a number of conditions or diseases involving fibrosis and proliferation, and where anti-fibrotic or anti-proliferative activity is beneficial.
Claims47
A compound represented by Formula (I):
- or an E or Z isomer thereof, syn or anti isomer thereof, an optically pure isomer thereof, or pharmaceutically acceptable salt thereof, wherein:
- X is a triazole, which is optionally substituted with one or more independent R5 substituents;
- R1 and R2 are each independently hydrogen or lower alkyl;
- A is
- or an aryl, either of which is optionally substituted with one or more independent R5 substituents;
- R3 and R4 are each independently hydrogen or lower alkyl;
- or R3 with R4, taken together with the carbon atom to which they are attached, form a carbonyl or 3-10 membered saturated or unsaturated monocyclic or polycyclic ring, wherein said ring is optionally substituted with one or more R5;
- each occurrence of R5 is independently hydrogen, halogen, cyano, hydroxy, nitro, —SO2NR6R7, —CONR6R7 or —NR6R7, haloalkyl, or lower alkyl group;
- and
- R6 and R7 are each independently hydrogen or a lower alkyl group.
7 more elements
A compound of Formula (I) represented by Formula (II):
- or an E or Z isomer thereof, syn or anti isomer thereof, an optically pure isomer thereof, or pharmaceutically acceptable salt thereof, wherein:
- X is a triazole, which is optionally substituted with one or more independent R5 substituents;
- R1 and R2 are each independently hydrogen or lower alkyl;
- one or more R5, each independently hydrogen, halogen, cyano, hydroxy, nitro, —SO2NR6R7, —CONR6R7 or —NR6R7, haloalkyl, or lower alkyl group;
- and
- R6 and R7 are each independently hydrogen or a lower alkyl group.
3 more elements
A compound of Formula (I) represented by Formula (III):
- or an E or Z isomer thereof, syn or anti isomer thereof, an optically pure isomer thereof, or pharmaceutically acceptable salt thereof, wherein:
- X is a triazole, which is optionally substituted with one or more independent R5 substituents;
- R1 and R2 are each independently hydrogen or lower alkyl;
- is optionally substituted with one or more independent R5 substituents;
- R3 and R4 are each independently hydrogen or lower alkyl;
- or R3 with R4, taken together with the carbon atom to which they are attached, form a carbonyl or 3-10 membered saturated or unsaturated monocyclic or polycyclic ring, wherein said ring is optionally substituted with one or more R5;
- each occurrence of R5 is independently hydrogen, halogen, cyano, hydroxy, nitro, —SO2NR6R7, —CONR6R7 or —NR6R7, haloalkyl, or lower alkyl group;
- and
- R6 and R7 are each independently hydrogen or a lower alkyl group.
6 more elements
Dependencies are inferred from the claim text.